Comparative Pharmacology
Head-to-head clinical analysis: CONRAY versus OMNIPAQUE 210.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY versus OMNIPAQUE 210.
CONRAY vs OMNIPAQUE 210
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
Radiopaque contrast agent that contains iodine, which attenuates X-rays and provides radiographic visualization of vascular structures and organs. It does not have a pharmacological mechanism of action.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
Intravascular administration: 50-150 mL (10-30 g iodine) as bolus or infusion, based on procedure (CT, angiography, urography). Intravenous infusion for CT: 100-200 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). In neonates, half-life is 6-12 hours due to immature renal function.
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Renal: ~95% unchanged within 24 hours via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent